Evidence map›Paper›PMID 35979524›Full record

ArticleSkin appendage disorders2022

Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts.

Jonathan W Rick, Devea R De, Terri Shih, Afsaneh Alavi, Joslyn S Kirby, Haley B Naik, John W Frew, Christopher J Sayed, Jennifer L Hsiao, Vivian Y Shi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Skin appendage disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 2 countries.

Jonathan W RickDepartment of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Devea R DeJacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.
Terri ShihDavid Geffen School of Medicine, University of California, Los Angeles, California, USA.
Afsaneh AlaviDepartment of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
Joslyn S KirbyDepartment of Dermatology Hershey, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
Haley B NaikDepartment of Dermatology, University of California, San Francisco, San Francisco, California, USA.
John W FrewDepartment of Dermatology, Liverpool Hospital, Sydney, New South Wales, Australia.
Christopher J SayedDepartment of Dermatology Chapel Hill, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Jennifer L HsiaoDivision of Dermatology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Vivian Y ShiDepartment of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
University of Arkansas for Medical Sciences · USUniversity of California, Los Angeles · USJacobs (United States) · USLiverpool Hospital · AUMayo Clinic · USPenn State Milton S. Hershey Medical Center · USUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hidradenitis suppurativa (HS) patients may be at increased risk of COVID-19 infection and complications from their medications and comorbidities. There is a lack of expert consensus on recommendations for the COVID-19 vaccine for HS patients. Herein, we aim to provide expert-driven consensus recommendations regarding COVID-19 vaccinations in HS patients. Methods: A modified Delphi consensus survey developed by a core committee of 7 dermatologist HS experts consisting of 4 demographic questions and 12 practice statements was distributed to the US HS Foundation-sponsored provider listserv. Participants were attending physician HS experts. Survey results were to be reviewed by the core group and revised and resubmitted until consensus (≥70% agreement) was achieved. Results: Among the 33 survey participants, there were 30 (87%) dermatologists, 1 general surgeon, 1 plastic surgeon, and 1 rheumatologist. Consensus for all 12 statements on vaccine counseling and HS treatment counseling was achieved after the first round. Discussion/Conclusion: For now, this consensus can serve as a resource for clinicians discussing COVID-19 vaccination with their HS patients. These recommendations will need to be updated as new evidence on COVID-19 emerges.

Indexed as

COVID-19Expert consensusGuidelinesHidradenitis suppurativaImmunomodulatorsVaccination

Identifiers

PMID35979524
PMCPMC9274824
OpenAlexW4206598261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.